PCN137 COST COMPARISON OF ADVERSE EVENTS AND TREATMENT ADMINISTRATION OF LURBINECTEDIN VERSUS INTRAVENOUS TOPOTECAN FOR RELAPSED SMALL CELL LUNG CANCER IN SPAIN AND THE UNITED KINGDOM
Abstract
Authors
B. García San Andrés S. Ubi R. Alvarez-Alvarez C. Barwood M.E. Olmedo-García M. Foster